Log in
Enquire now
‌

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT00087789
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT000877890
Health Conditions in Trial
Alzheimer's disease
Alzheimer's disease
0
Trial Recruitment Size
100
Trial Sponsor
Sangamo Therapeutics
Sangamo Therapeutics
0
Trial Collaborator
Ceregene
Ceregene
0
Clinical Trial Start Date
2004
0
Primary Completion Date
2010
0
Study Completion Date
2010
0
Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 10
Participating Facility
Rush University Medical Center
Rush University Medical Center
0
Official Name
A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease0
Last Updated
November 10, 2022
0
Allocation Type
Non-Randomized0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary

This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total of four (Dose A and B) and six (Dose C) injections to target the basal forebrain region of the brain containing the nucleus basalis of Meynert (NBM). All study participants will be observed for a 24-month period and then followed annually.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.